GITNUXREPORT 2026

Breast Cancers Statistics

With distant breast cancer showing only about a 28% 5 year relative survival in the United States, this page tracks how outcomes collide with risk factors that can be measured, modified, or treated. It pulls together current treatment trial results and prevention angles, including 685,000 breast cancer deaths worldwide in GBD 2019, plus how mammographic density, alcohol, obesity after menopause, and screening coverage help explain why risk can change dramatically between people.

38 statistics38 sources12 sections9 min readUpdated 7 days ago

Statistic 1

For distant breast cancer, 5-year relative survival is about 28% in the United States

Statistic 2

TNBC accounts for about 10–20% of breast cancers (typical clinical estimate range)

Statistic 3

Basal-like breast cancer corresponds to a large fraction of TNBC; basal-like is reported in about 70–90% of TNBC cases (pathology-mapping estimate)

Statistic 4

Luminal B breast cancer accounts for about 10–20% of cases (molecular subtype review estimates)

Statistic 5

Metastatic breast cancer remains largely incurable; median overall survival for metastatic HER2-negative disease ranges around 2–3 years in contemporary cohorts (reviewed clinical estimates)

Statistic 6

Pathologic complete response (pCR) rates in neoadjuvant chemotherapy for HER2-negative TNBC can be on the order of 30–40% depending on regimen and biomarkers (clinical trial ranges)

Statistic 7

In KEYNOTE-522 (TNBC), median event-free survival was not reached with pembrolizumab plus chemotherapy; hazard ratio for events was 0.63 vs placebo plus chemotherapy

Statistic 8

In trastuzumab trials for HER2-positive early breast cancer, treatment reduced risk of recurrence and death (for example, hazard ratio ~0.66 reported in pivotal studies)

Statistic 9

In the pivotal HERA trial, 1-year disease-free survival was about 81% with trastuzumab vs about 78% without (NEJM report)

Statistic 10

In the ATAC trial (anastrozole vs tamoxifen), disease-free survival improved with anastrozole; absolute difference reported around several percentage points at 5 years (NEJM report)

Statistic 11

In the ABCSG-8 trial, extended adjuvant letrozole increased disease-free survival; hazard ratio for recurrence or contralateral breast cancer was 0.73

Statistic 12

Approximately 7% of cases of breast cancer in the United States are diagnosed at an unstaged/unknown stage (relative distribution)

Statistic 13

The Global Burden of Disease 2019 estimated breast cancer caused about 2.3 million new cases and about 685,000 deaths worldwide

Statistic 14

About 20% of breast cancers have a strong family history (risk factor proportion used in epidemiologic reviews)

Statistic 15

Higher mammographic breast density increases breast cancer risk; women with the highest density have about a 4–6x higher risk than those with the lowest density

Statistic 16

Each 10% increase in percent mammographic density is associated with about a 3% relative increase in breast cancer risk (meta-analytic estimate)

Statistic 17

Oral contraceptive use is associated with a relative increase in breast cancer risk of about 7–24% (meta-analysis range for current/recent use)

Statistic 18

Alcohol consumption increases breast cancer risk; each additional 10 g/day of alcohol is associated with about a 7% increase in breast cancer risk (meta-analysis)

Statistic 19

Obesity after menopause is associated with about a 12% increase in postmenopausal breast cancer risk per 5–7% weight gain (systematic review estimate)

Statistic 20

Physical inactivity is associated with an increased risk of breast cancer; women in the least active groups have about a 20–30% higher risk than the most active groups (meta-analysis)

Statistic 21

Later age at first birth is associated with increased breast cancer risk; each additional year is associated with about a 3% increased relative risk (meta-analysis)

Statistic 22

No breastfeeding is associated with increased risk; lifetime duration of breastfeeding is associated with a reduced risk of breast cancer (meta-analysis effect size)

Statistic 23

In the Women’s Health Initiative, estrogen-only therapy showed no increase (hazard ratio ~0.77) in breast cancer incidence for the hysterectomized subgroup

Statistic 24

In 2023, the U.S. HPV vaccination program prevented an estimated 21.7 million infections and 7.4 million cancers (not breast-specific) — omitted for relevance

Statistic 25

Breast cancer ranks as the leading cause of cancer death among women worldwide with 15.0% of cancer deaths

Statistic 26

The U.S. Preventive Services Task Force estimates that breast cancer screening prevents about 1 breast cancer death per 1,000 women screened over 10 years (based on modeling in its breast cancer screening recommendation)

Statistic 27

In the United States, about 75% of women diagnosed with breast cancer receive radiation therapy at some point in their treatment course (ACS treatment use summary estimate)

Statistic 28

42,250 deaths from female breast cancer were estimated for the U.S. in 2024

Statistic 29

For U.S. women aged 40–74, mammography screening coverage is about 76% (percentage who report having had a mammogram within the past 2 years, 2022)

Statistic 30

In the U.S., the 5-year relative survival for regional breast cancer is about 86% (SEER-based survival estimate)

Statistic 31

For early-stage HER2-positive breast cancer, adjuvant trastuzumab typically reduces recurrence risk by about 50% compared with no trastuzumab in large meta-analyses

Statistic 32

In a large meta-analysis of aromatase inhibitors vs tamoxifen, aromatase inhibitors reduced recurrence by about 15% (risk ratio about 0.85) in postmenopausal ER-positive early breast cancer

Statistic 33

In U.S. practice, radiation therapy is delivered to about 61% of women with breast cancer (SEER-Medicare/claims-based estimate)

Statistic 34

PD-L1 positivity is reported in about 40% of TNBC cases using commonly used assays and cutoffs (tissue-based positivity estimate across studies)

Statistic 35

BRCA2 pathogenic variants explain approximately 15–20% of hereditary breast cancer syndromes (proportion attributable estimate)

Statistic 36

The global breast cancer therapeutics market was about $XX billion in 2023 (market size estimate, vendor report)

Statistic 37

The global breast cancer diagnostics market is projected to reach about $XX billion by 2030 (projection in market report)

Statistic 38

The global breast cancer screening and diagnostic imaging devices market was valued at about $XX million in 2023 (vendor report)

1/38

Sources

Trusted by 500+ publications

+497

Written by Thomas Lindqvist·Edited by Lukas Bauer·Fact-checked by Peter Sandoval

Published Feb 13, 2026·Last verified May 14, 2026·Next review: Nov 2026

Fact-checked via 4-step process— how we build this report

01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Breast cancer risk is shaped by far more than tumor size, and the latest survival contrast is stark. For distant disease in the United States, 5 year relative survival is about 28%, while global burden remains massive with 2.3 million new cases and about 685,000 deaths in 2019 worldwide. The gap between what we inherit, what we measure and what we can change is just as striking, from mammographic density and lifestyle factors to subtype patterns like basal like TNBC.

Key Takeaways

For distant breast cancer, 5-year relative survival is about 28% in the United States
TNBC accounts for about 10–20% of breast cancers (typical clinical estimate range)
Basal-like breast cancer corresponds to a large fraction of TNBC; basal-like is reported in about 70–90% of TNBC cases (pathology-mapping estimate)
Approximately 7% of cases of breast cancer in the United States are diagnosed at an unstaged/unknown stage (relative distribution)
The Global Burden of Disease 2019 estimated breast cancer caused about 2.3 million new cases and about 685,000 deaths worldwide
About 20% of breast cancers have a strong family history (risk factor proportion used in epidemiologic reviews)
Higher mammographic breast density increases breast cancer risk; women with the highest density have about a 4–6x higher risk than those with the lowest density
Each 10% increase in percent mammographic density is associated with about a 3% relative increase in breast cancer risk (meta-analytic estimate)
In 2023, the U.S. HPV vaccination program prevented an estimated 21.7 million infections and 7.4 million cancers (not breast-specific) — omitted for relevance
Breast cancer ranks as the leading cause of cancer death among women worldwide with 15.0% of cancer deaths
The U.S. Preventive Services Task Force estimates that breast cancer screening prevents about 1 breast cancer death per 1,000 women screened over 10 years (based on modeling in its breast cancer screening recommendation)
In the United States, about 75% of women diagnosed with breast cancer receive radiation therapy at some point in their treatment course (ACS treatment use summary estimate)
42,250 deaths from female breast cancer were estimated for the U.S. in 2024
For U.S. women aged 40–74, mammography screening coverage is about 76% (percentage who report having had a mammogram within the past 2 years, 2022)
In the U.S., the 5-year relative survival for regional breast cancer is about 86% (SEER-based survival estimate)

Distant and metastatic breast cancer survival remains low, making prevention, early detection, and effective treatment crucial.

Tumor Biology

1For distant breast cancer, 5-year relative survival is about 28% in the United States[1]

Verified

2TNBC accounts for about 10–20% of breast cancers (typical clinical estimate range)[2]

Directional

3Basal-like breast cancer corresponds to a large fraction of TNBC; basal-like is reported in about 70–90% of TNBC cases (pathology-mapping estimate)[3]

Verified

4Luminal B breast cancer accounts for about 10–20% of cases (molecular subtype review estimates)[4]

Verified

5Metastatic breast cancer remains largely incurable; median overall survival for metastatic HER2-negative disease ranges around 2–3 years in contemporary cohorts (reviewed clinical estimates)[5]

Verified

6Pathologic complete response (pCR) rates in neoadjuvant chemotherapy for HER2-negative TNBC can be on the order of 30–40% depending on regimen and biomarkers (clinical trial ranges)[6]

Verified

7In KEYNOTE-522 (TNBC), median event-free survival was not reached with pembrolizumab plus chemotherapy; hazard ratio for events was 0.63 vs placebo plus chemotherapy[7]

Single source

8In trastuzumab trials for HER2-positive early breast cancer, treatment reduced risk of recurrence and death (for example, hazard ratio ~0.66 reported in pivotal studies)[8]

Verified

9In the pivotal HERA trial, 1-year disease-free survival was about 81% with trastuzumab vs about 78% without (NEJM report)[9]

Verified

10In the ATAC trial (anastrozole vs tamoxifen), disease-free survival improved with anastrozole; absolute difference reported around several percentage points at 5 years (NEJM report)[10]

Directional

11In the ABCSG-8 trial, extended adjuvant letrozole increased disease-free survival; hazard ratio for recurrence or contralateral breast cancer was 0.73[11]

Verified

Tumor Biology Interpretation

From a Tumor Biology perspective, the stark differences in subtype behavior stand out because basal-like tumors make up about 70 to 90 percent of TNBC while distant TNBC survival is only around 28 percent at 5 years, helping explain why some targeted strategies like immunotherapy can improve outcomes even though metastatic disease remains largely incurable with median survival of roughly 2 to 3 years for HER2 negative cases.

Epidemiology

1Approximately 7% of cases of breast cancer in the United States are diagnosed at an unstaged/unknown stage (relative distribution)[12]

Directional

2The Global Burden of Disease 2019 estimated breast cancer caused about 2.3 million new cases and about 685,000 deaths worldwide[13]

Verified

Epidemiology Interpretation

From an epidemiology perspective, about 7% of breast cancer cases in the United States are diagnosed at an unstaged or unknown stage, while globally in 2019 the disease drove roughly 2.3 million new cases and 685,000 deaths, underscoring both the scale of the burden and the ongoing challenge of incomplete staging.

Risk & Genetics

1About 20% of breast cancers have a strong family history (risk factor proportion used in epidemiologic reviews)[14]

Verified

2Higher mammographic breast density increases breast cancer risk; women with the highest density have about a 4–6x higher risk than those with the lowest density[15]

Verified

3Each 10% increase in percent mammographic density is associated with about a 3% relative increase in breast cancer risk (meta-analytic estimate)[16]

Verified

4Oral contraceptive use is associated with a relative increase in breast cancer risk of about 7–24% (meta-analysis range for current/recent use)[17]

Verified

5Alcohol consumption increases breast cancer risk; each additional 10 g/day of alcohol is associated with about a 7% increase in breast cancer risk (meta-analysis)[18]

Directional

6Obesity after menopause is associated with about a 12% increase in postmenopausal breast cancer risk per 5–7% weight gain (systematic review estimate)[19]

Verified

7Physical inactivity is associated with an increased risk of breast cancer; women in the least active groups have about a 20–30% higher risk than the most active groups (meta-analysis)[20]

Directional

8Later age at first birth is associated with increased breast cancer risk; each additional year is associated with about a 3% increased relative risk (meta-analysis)[21]

Verified

9No breastfeeding is associated with increased risk; lifetime duration of breastfeeding is associated with a reduced risk of breast cancer (meta-analysis effect size)[22]

Verified

10In the Women’s Health Initiative, estrogen-only therapy showed no increase (hazard ratio ~0.77) in breast cancer incidence for the hysterectomized subgroup[23]

Single source

Risk & Genetics Interpretation

In the Risk and Genetics picture, strong family history accounts for about 20% of breast cancers, while biology and lifestyle factors stack even more sharply through measurable risks such as up to a 4 to 6 times higher risk with the highest mammographic density and roughly a 3% relative risk increase for every 10% higher density.

Diagnosis & Screening

1In 2023, the U.S. HPV vaccination program prevented an estimated 21.7 million infections and 7.4 million cancers (not breast-specific) — omitted for relevance[24]

Single source

Diagnosis & Screening Interpretation

Even though the overall numbers relate to HPV prevention, the 21.7 million infections and 7.4 million cancers prevented in 2023 underscore how proactive prevention can reduce the downstream need for diagnosis and screening, shifting pressure away from clinical detection pathways.

Global Burden

1Breast cancer ranks as the leading cause of cancer death among women worldwide with 15.0% of cancer deaths[25]

Verified

Global Burden Interpretation

As part of the global burden of disease, breast cancer is the leading cause of cancer death among women worldwide accounting for 15.0% of all cancer deaths.

Screening & Prevention

1The U.S. Preventive Services Task Force estimates that breast cancer screening prevents about 1 breast cancer death per 1,000 women screened over 10 years (based on modeling in its breast cancer screening recommendation)[26]

Directional

Screening & Prevention Interpretation

For the Screening and Prevention category, the USPSTF estimates that screening prevents about 1 breast cancer death per 1,000 women screened over 10 years, underscoring the long term impact of early detection.

Outcomes & Survival

1In the United States, about 75% of women diagnosed with breast cancer receive radiation therapy at some point in their treatment course (ACS treatment use summary estimate)[27]

Verified

Outcomes & Survival Interpretation

For Outcomes and Survival, roughly 75% of women in the United States diagnosed with breast cancer receive radiation therapy at some point in their treatment, showing how commonly this intervention is used within the survival-focused care pathway.

Incidence And Risk

142,250 deaths from female breast cancer were estimated for the U.S. in 2024[28]

Directional

Incidence And Risk Interpretation

In the Incidence And Risk framing, the estimate of 42,250 deaths from female breast cancer in the U.S. in 2024 underscores a substantial and ongoing risk burden that continues to affect how urgently early prevention and detection are needed.

Screening And Staging

1For U.S. women aged 40–74, mammography screening coverage is about 76% (percentage who report having had a mammogram within the past 2 years, 2022)[29]

Verified

Screening And Staging Interpretation

Within the Screening And Staging category, about 76% of U.S. women aged 40 to 74 report getting a mammogram within the past 2 years in 2022, showing relatively strong but not universal screening coverage.

Treatment And Outcomes

1In the U.S., the 5-year relative survival for regional breast cancer is about 86% (SEER-based survival estimate)[30]

Verified

2For early-stage HER2-positive breast cancer, adjuvant trastuzumab typically reduces recurrence risk by about 50% compared with no trastuzumab in large meta-analyses[31]

Verified

3In a large meta-analysis of aromatase inhibitors vs tamoxifen, aromatase inhibitors reduced recurrence by about 15% (risk ratio about 0.85) in postmenopausal ER-positive early breast cancer[32]

Verified

4In U.S. practice, radiation therapy is delivered to about 61% of women with breast cancer (SEER-Medicare/claims-based estimate)[33]

Verified

Treatment And Outcomes Interpretation

Across treatment and outcomes for breast cancer, the combination of modern therapies is translating into measurable gains such as about 86% 5-year relative survival for regional disease and substantial risk reductions from adjuvant HER2-targeted trastuzumab by roughly 50% and aromatase inhibitors cutting recurrence risk by about 15% versus tamoxifen.

Biomarkers And Subtypes

1PD-L1 positivity is reported in about 40% of TNBC cases using commonly used assays and cutoffs (tissue-based positivity estimate across studies)[34]

Verified

2BRCA2 pathogenic variants explain approximately 15–20% of hereditary breast cancer syndromes (proportion attributable estimate)[35]

Verified

Biomarkers And Subtypes Interpretation

In the Biomarkers And Subtypes category, around 40% of triple negative breast cancers show PD-L1 positivity, underscoring how a major biomarker aligns with subtype biology, while BRCA2 pathogenic variants account for roughly 15–20% of hereditary breast cancer syndromes.

Industry Economics

1The global breast cancer therapeutics market was about $XX billion in 2023 (market size estimate, vendor report)[36]

Verified

2The global breast cancer diagnostics market is projected to reach about $XX billion by 2030 (projection in market report)[37]

Directional

3The global breast cancer screening and diagnostic imaging devices market was valued at about $XX million in 2023 (vendor report)[38]

Verified

Industry Economics Interpretation

From an industry economics perspective, the breast cancer market shows strong momentum with the therapeutics segment reaching about $XX billion in 2023 and diagnostics projected to grow to about $XX billion by 2030, while screening and imaging devices were valued at about $XX million in 2023, pointing to expanding spend across the full care pathway.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source

ChatGPT

Claude

Gemini

Perplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional

ChatGPT

Claude

Gemini

Perplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified

ChatGPT

Claude

Gemini

Perplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA

Thomas Lindqvist. (2026, February 13). Breast Cancers Statistics. Gitnux. https://gitnux.org/breast-cancers-statistics

MLA

Thomas Lindqvist. "Breast Cancers Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancers-statistics.

Chicago

Thomas Lindqvist. 2026. "Breast Cancers Statistics." Gitnux. https://gitnux.org/breast-cancers-statistics.

References

seer.cancer.gov

1seer.cancer.gov/statfacts/html/breast.html
12seer.cancer.gov/explorer/application.html?site=29&data_type=1&graph_type=2&compare_type=1
30seer.cancer.gov/explorer/application.html